Group UnCh (N=142) | Group InCr (N=34) | Group DeCr (N=173) | All (N=349) | P-value* | |
---|---|---|---|---|---|
Age | 58 (16–83) | 56 (25–83) | 57 (18–84) | 58 (16–84) | 0.96 |
Gender (% women) | 62 | 56 | 68 | 64 | 0.33** |
Disease duration (months) | 6.0 (1–13) | 3.5 (1–12) | 6.0 (1–21) | 6,0 (1–21) | 0.10 |
DAS28 | 5.4 (0.5-7.9) | 5.5 (0.5-8.0) | 5.1 (2.3-8.1) | 5,3 (0,5-8,1) | 0.06 |
HAQ | 0.9 (0–2.6) | 1.3 (0–2.3) | 0.9 (0–2.5) | 0,9 (0–2,6) | 0.10 |
ESR (mm/H) | 33 (2–110) | 42 (2–140) | 27 (2–115) | 31 (2–140) | 0.006 |
CRP (mg/L) | 22.0 (4–186) | 29.5 (3–159) | 19.0 (4–228) | 21 (3–228) | 0.40 |
RF positive (%) | 61 | 67 | 56 | 59 | 0.46** |
Anti-CCP (%) | 58 | 61 | 56 | 57 | 0.86** |
COMP (U/L) | 11.9 (6.1-26.8) | 9.6 (5.6-19.3) | 13.8 (4.5-32.0) | 12.7 (4.5-32.0) | <0.001 |
Erosion score | 0 (0–44) | 0 (0–20) | 0 (0–15) | 0 (0–44) | 0.68 |
JSN score | 0 (0–40) | 0 (0–15) | 0 (0–33) | 0 (0–40) | 0.41 |
Total Sharp score | 1 (0–84) | 2 (0–34) | 0.25 (0–35) | 1 (0–84) | 0.52 |